ATRIPAnnual meeting

Parma, ItalySeptember 4 – 6, 2006

Main Hall, Chamber of Commerce of Parma

Sensitive Issues of Health and Patent Law in FTAs Recently Executed by the USA:

The Latin American Situation

by 

Horacio RANGEL-ORTIZDr. jur. Professor of International Intellectual Property Law, School of Law, National University of Mexico, (UNAM) and Universidad Panamericana (UP), Mexico City. Attorney at Law. President of ATRIP (1997-1999) and of the Mexican Group of AIPPI (1992-1995). President of the International Treaties Committee of the Mexican Group of AIPPI.

ATRIP

NAFTA Standards (1993)

TRIPS Standards (1994)

TRIPS Plus Standards (2002)

PATENTand

HEALTHIssues

U.S. Trade Promotion Authority

Act (2002)

and

DOHA DECLARATION on the TRIPS

Agreement and Health (2001)

Post-NAFTA Times

Developments incorporated in FTAs recently executed by the U.S. with Latin American nations

Pharmaceutical and Agricultural Chemical Products

OTHER BILATERAL U.S. TRADE AGREEMENTS (2004)

NORTH AFRICA (Morocco)

THE PERSIAN GULF (Bahrain)

OCEANIA (Australia)

POST-NAFTA INNOVATIONS

Protection of Undisclosed Information and Marketing Approval Proceedings

Marketing Approval Requested by Third Parties Other than the Patentee

Extension of the Patent Term and Unreasonable Delays at the Patent Office

Extension of the Patent Term and Unreasonable Delays at the Marketing Approval Process

Identity of a Third Party Requesting Marketing Approval During the Term of the Patent

Patentability of New Uses or Methods of Using Known Products

Exhaustion of Patent Rights

Traditional Knowledge, Genetic Resources and Equitable Sharing of Benefits

Bilateral Trade Agreements do not Derogate Understandings Under the Doha Declaration on TRIPS and Public Health

Protection of Undisclosed Information Involved in Marketing Approval

Proceedings

Five-year period from the date of approval: pharmaceutical productTen-year period from the date of approval: agricultural chemical productNAFTA 1993

Chile 2003 Yes

CAFTA 2004 Yes

Peru 2006 Yes

Colombia 2006 Yes

Morocco 2006 Yes

Bahrain 2006 Yes

Australia 2006 Yes

Obligation Not to Grant Marketing Approval to Third

Parties Prior to the Expiration of the Patent Term of

Pharmaceutical ProductsNAFTA 1993 No

Chile 2003 Yes

CAFTA 2004 Yes

Peru 2006 Yes

Colombia 2006 Yes

Morocco 2006 Yes

Bahrain 2006 Yes

Australia 2006 Yes

Extension of the Patent Term to Compensate for Unreasonable

Delays at the Patent Office.

NAFTA 1993 No

Chile 2003 Yes

CAFTA 2004 Yes

Peru 2006 Yes

Colombia 2006 Yes

Morocco 2006 Yes

Bahrain 2006 Yes

Australia 2006 Yes

Extension of the Patent Term to Compensate for Unreasonable

Delays Resulting from the Marketing Approval Process

NAFTA 1993 No

Chile 2003 Yes

CAFTA 2004 Yes

Peru 2006 Yes

Colombia 2006 Yes

Morocco 2006 Yes

Bahrain 2006 Yes

Australia 2006 Yes

Obligation to Make Available to the Patent Owner the Identity of a Third Party Requesting Marketing Approval During the Term of the

PatentNAFTA 1993 No

Chile 2003 Yes

CAFTA 2004 Yes

Peru 2006 Yes

Colombia 2006 Yes

Morocco 2006 Yes

Bahrain 2006 Yes

Australia 2006 Yes

Patentability of New Uses or Methods of Using Known Products

NAFTA 1993 No

Chile 2003 No

CAFTA 2004 No

Peru 2006 No

Colombia 2006 No

Morocco 2006 Yes

Bahrain 2006 Yes

Australia 2006 Yes

Exhaustion of Patent Rights

NAFTA 1993 No

Chile 2003 No

CAFTA 2004 No

Peru 2006 No

Colombia 2006 No

Morocco 2006 Yes

Bahrain 2006 Yes

Australia 2006 Yes

Traditional Knowledge, Genetic Resources and Equitable Sharing of Benefits

NAFTA 1993 No

Chile 2003 No

CAFTA 2004 No

Peru 2006 No

Colombia 2006 “Yes”

Morocco 2006 No

Bahrain 2006 No

Australia 2006 No

Bilateral Trade Agreements do not Derogate Understandings Previously

Adopted Under the Doha Declaration on TRIPS and Public Health

NAFTA 1993 No

Chile 2003 No

CAFTA 2004 Yes

Peru 2006 Yes

Colombia 2006 Yes

Morocco 2006

Bahrain 2006

Australia 2006

CONCLUSIONS

www.horaciorangelortiz.org.mx